1. kickoff-deck-generateSUCCEEDED
{
"output": {
"deckOutline": {
"Title": "Kickoff Deck Outline: US Payer Coverage and Market Access Research for Anti-Obesity Therapies",
"1. Deck objective": {
"objective": "Align the project team on the research scope, key questions, source strategy, and delivery plan for assessing US payer coverage, evidence expectations, and market access barriers for anti-obesity pharmacotherapies."
},
"6. Immediate next steps": {
"actions": [
{
"owner": "Client + project lead",
"action": "Confirm final research scope, payer universe, and competitor set"
},
{
"owner": "Client",
"action": "Share any existing market access materials and prior analyses"
},
{
"owner": "Project team",
"action": "Finalize source strategy and analytic framework"
},
{
"owner": "Client + project lead",
"action": "Set review cadence and milestone dates"
}
]
},
"5. Risks and open questions": {
"risks": [
"Payer policies may change during the research window.",
"Public documentation may not fully reflect real decision-making.",
"Coverage approaches may vary significantly by payer segment and line of business.",
"Evidence expectations may differ across commercial and MA plans."
],
"open_questions": [
"Which payers are priority versus illustrative?",
"Should the analysis separate obesity-only policies from broader cardiometabolic management?",
"How deep should competitor contracting analysis go?",
"What is the minimum evidence package needed to support launch planning?"
]
},
"4. Materials and inputs to request": {
"materials": [
"List of target payers, PBMs, and Medicare Advantage organizations",
"Any internal payer strategy or launch planning materials",
"Priority competitor and product list",
"Previous market access or payer research",
"Preferred output format and level of detail",
"Any known policy documents or stakeholder insights already collected"
],
"stakeholder_inputs": [
"Business questions the research must answer",
"Preferred evidence thresholds",
"Internal views on likely access barriers",
"Reviewers and approvers for interim/final outputs"
]
},
"3. Recommended kickoff deck outline": {
"slides": [
{
"purpose": "Set the why for the research and align on what the kickoff must confirm.",
"slideTitle": "Project purpose and kickoff objectives",
"keyTopicsToCover": [
"Business decision this research will inform",
"Intended use of findings for payer strategy and evidence planning",
"Expected end products and audiences"
],
"criticalDecisionsQuestionsConfirmations": [
"What decisions must this research enable?",
"Who will use the output and how?"
]
},
{
"purpose": "Define the exact coverage and access questions to be answered.",
"slideTitle": "Research scope and core questions",
"keyTopicsToCover": [
"US payer coverage and management of anti-obesity therapies",
"Commercial vs Medicare Advantage scope",
"Utilization management and value assessment dimensions"
],
"criticalDecisionsQuestionsConfirmations": [
"Which payer segments are in and out of scope?",
"Are specific products or classes to be emphasized?"
]
},
{
"purpose": "Align on known market dynamics and expected themes to test.",
"slideTitle": "What we know today: market context and working hypotheses",
"keyTopicsToCover": [
"Current payer scrutiny of obesity drug affordability and durability",
"Likely evidence thresholds for coverage and access",
"Potential differences by payer type"
],
"criticalDecisionsQuestionsConfirmations": [
"What hypotheses should the research validate or challenge?",
"Which assumptions require early validation?"
]
},
{
"purpose": "Translate the research question into a practical analytic framework.",
"slideTitle": "Coverage policy and access dimensions to assess",
"keyTopicsToCover": [
"Prior authorization",
"Step therapy",
"Formulary tiering/positioning",
"Reauthorization and adherence requirements",
"Exclusions and benefit design constraints"
],
"criticalDecisionsQuestionsConfirmations": [
"Which access levers matter most for the team?",
"Should benefit design barriers be analyzed separately?"
]
},
{
"purpose": "Clarify the evidence themes that influence payer decisions.",
"slideTitle": "Evidence and value criteria to evaluate",
"keyTopicsToCover": [
"Long-term outcomes",
"Cardiovascular benefit",
"Real-world adherence/persistence",
"Healthcare cost offsets",
"Budget impact and durability of weight loss"
],
"criticalDecisionsQuestionsConfirmations": [
"What evidence types are mandatory vs nice to have?",
"How should clinical vs economic evidence be weighted?"
]
},
{
"purpose": "Align on where insights will come from and how they will be prioritized.",
"slideTitle": "Source strategy and evidence hierarchy",
"keyTopicsToCover": [
"Published literature",
"Payer policy documents",
"Conference presentations",
"Advisory board insights",
"Reimbursement trend analyses",
"Gray literature"
],
"criticalDecisionsQuestionsConfirmations": [
"What sources are acceptable and required?",
"How will recency and credibility be prioritized?"
]
},
{
"purpose": "Define how competitor access strategies and contracting models will be assessed.",
"slideTitle": "Competitor and contracting landscape",
"keyTopicsToCover": [
"Competitor payer positioning",
"Emerging outcomes-based contracting",
"Implications for next-generation GLP-1/GIP therapies"
],
"criticalDecisionsQuestionsConfirmations": [
"Which competitors should be benchmarked?",
"Is contracting analysis directional or detailed?"
]
},
{
"purpose": "Confirm how the research will be executed and by whom.",
"slideTitle": "Workplan, timeline, and team roles",
"keyTopicsToCover": [
"Key workstreams",
"Internal roles and review points",
"Timing for interim and final readouts"
],
"criticalDecisionsQuestionsConfirmations": [
"What are the milestones and approval checkpoints?",
"Who owns client and internal inputs?"
]
},
{
"purpose": "Surface blockers that could affect quality, timing, or relevance.",
"slideTitle": "Open issues, risks, and dependencies",
"keyTopicsToCover": [
"Data availability",
"Rapid policy changes",
"Inconsistent payer policy transparency",
"Scope creep"
],
"criticalDecisionsQuestionsConfirmations": [
"What dependencies could delay the work?",
"What scope trade-offs are acceptable?"
]
},
{
"purpose": "Lock down actions needed to start the research efficiently.",
"slideTitle": "Immediate next steps",
"keyTopicsToCover": [
"Confirm payer list and comparator set",
"Confirm source priorities",
"Assign owners for inputs and review"
],
"criticalDecisionsQuestionsConfirmations": [
"What is due from the client and by when?",
"What is the date for the next working session?"
]
}
]
},
"2. What we know / assumptions / gaps": {
"gaps": [
"List of specific payers, PBMs, and MA plans to include.",
"Whether the output should be qualitative only or include a structured payer landscape matrix.",
"Preferred competitor set and therapy comparators.",
"Depth of coverage for outcomes-based contracting and economic evidence.",
"Definition of deliverable timing and level of source traceability required."
],
"assumptions": [
"The work will compare current payer management approaches across major national and regional plans.",
"The output will support launch planning for next-generation GLP-1/GIP therapies.",
"Competitor positioning and contracting trends are in scope as context for access strategy."
],
"known facts": [
"Geography is the United States.",
"Focus is on commercial payers, PBMs, and Medicare Advantage organizations.",
"Target topic is payer coverage, access, and value assessment trends for anti-obesity pharmacotherapies.",
"Primary objective is to inform payer engagement strategy, value proposition development, and evidence generation planning ahead of launch.",
"Priority topics include prior authorization, step therapy, formulary positioning, long-term outcomes, cardiovascular benefit, adherence, and cost offsets.",
"Sources should include both published and gray literature from the last 12 to 18 months."
]
}
}
},
"status": "completed",
"rawProviderText": "{\"deckOutline\":{\"Title\":\"Kickoff Deck Outline: US Payer Coverage and Market Access Research for Anti-Obesity Therapies\",\"1. Deck objective\":{\"objective\":\"Align the project team on the research scope, key questions, source strategy, and delivery plan for assessing US payer coverage, evidence expectations, and market access barriers for anti-obesity pharmacotherapies.\"},\"2. What we know / assumptions / gaps\":{\"known facts\":[\"Geography is the United States.\",\"Focus is on commercial payers, PBMs, and Medicare Advantage organizations.\",\"Target topic is payer coverage, access, and value assessment trends for anti-obesity pharmacotherapies.\",\"Primary objective is to inform payer engagement strategy, value proposition development, and evidence generation planning ahead of launch.\",\"Priority topics include prior authorization, step therapy, formulary positioning, long-term outcomes, cardiovascular benefit, adherence, and cost offsets.\",\"Sources should include both published and gray literature from the last 12 to 18 months.\"],\"assumptions\":[\"The work will compare current payer management approaches across major national and regional plans.\",\"The output will support launch planning for next-generation GLP-1/GIP therapies.\",\"Competitor positioning and contracting trends are in scope as context for access strategy.\"],\"gaps\":[\"List of specific payers, PBMs, and MA plans to include.\",\"Whether the output should be qualitative only or include a structured payer landscape matrix.\",\"Preferred competitor set and therapy comparators.\",\"Depth of coverage for outcomes-based contracting and economic evidence.\",\"Definition of deliverable timing and level of source traceability required.\"]},\"3. Recommended kickoff deck outline\":{\"slides\":[{\"slideTitle\":\"Project purpose and kickoff objectives\",\"purpose\":\"Set the why for the research and align on what the kickoff must confirm.\",\"keyTopicsToCover\":[\"Business decision this research will inform\",\"Intended use of findings for payer strategy and evidence planning\",\"Expected end products and audiences\"],\"criticalDecisionsQuestionsConfirmations\":[\"What decisions must this research enable?\",\"Who will use the output and how?\"]},{\"slideTitle\":\"Research scope and core questions\",\"purpose\":\"Define the exact coverage and access questions to be answered.\",\"keyTopicsToCover\":[\"US payer coverage and management of anti-obesity therapies\",\"Commercial vs Medicare Advantage scope\",\"Utilization management and value assessment dimensions\"],\"criticalDecisionsQuestionsConfirmations\":[\"Which payer segments are in and out of scope?\",\"Are specific products or classes to be emphasized?\"]},{\"slideTitle\":\"What we know today: market context and working hypotheses\",\"purpose\":\"Align on known market dynamics and expected themes to test.\",\"keyTopicsToCover\":[\"Current payer scrutiny of obesity drug affordability and durability\",\"Likely evidence thresholds for coverage and access\",\"Potential differences by payer type\"],\"criticalDecisionsQuestionsConfirmations\":[\"What hypotheses should the research validate or challenge?\",\"Which assumptions require early validation?\"]},{\"slideTitle\":\"Coverage policy and access dimensions to assess\",\"purpose\":\"Translate the research question into a practical analytic framework.\",\"keyTopicsToCover\":[\"Prior authorization\",\"Step therapy\",\"Formulary tiering/positioning\",\"Reauthorization and adherence requirements\",\"Exclusions and benefit design constraints\"],\"criticalDecisionsQuestionsConfirmations\":[\"Which access levers matter most for the team?\",\"Should benefit design barriers be analyzed separately?\"]},{\"slideTitle\":\"Evidence and value criteria to evaluate\",\"purpose\":\"Clarify the evidence themes that influence payer decisions.\",\"keyTopicsToCover\":[\"Long-term outcomes\",\"Cardiovascular benefit\",\"Real-world adherence/persistence\",\"Healthcare cost offsets\",\"Budget impact and durability of weight loss\"],\"criticalDecisionsQuestionsConfirmations\":[\"What evidence types are mandatory vs nice to have?\",\"How should clinical vs economic evidence be weighted?\"]},{\"slideTitle\":\"Source strategy and evidence hierarchy\",\"purpose\":\"Align on where insights will come from and how they will be prioritized.\",\"keyTopicsToCover\":[\"Published literature\",\"Payer policy documents\",\"Conference presentations\",\"Advisory board insights\",\"Reimbursement trend analyses\",\"Gray literature\"],\"criticalDecisionsQuestionsConfirmations\":[\"What sources are acceptable and required?\",\"How will recency and credibility be prioritized?\"]},{\"slideTitle\":\"Competitor and contracting landscape\",\"purpose\":\"Define how competitor access strategies and contracting models will be assessed.\",\"keyTopicsToCover\":[\"Competitor payer positioning\",\"Emerging outcomes-based contracting\",\"Implications for next-generation GLP-1/GIP therapies\"],\"criticalDecisionsQuestionsConfirmations\":[\"Which competitors should be benchmarked?\",\"Is contracting analysis directional or detailed?\"]},{\"slideTitle\":\"Workplan, timeline, and team roles\",\"purpose\":\"Confirm how the research will be executed and by whom.\",\"keyTopicsToCover\":[\"Key workstreams\",\"Internal roles and review points\",\"Timing for interim and final readouts\"],\"criticalDecisionsQuestionsConfirmations\":[\"What are the milestones and approval checkpoints?\",\"Who owns client and internal inputs?\"]},{\"slideTitle\":\"Open issues, risks, and dependencies\",\"purpose\":\"Surface blockers that could affect quality, timing, or relevance.\",\"keyTopicsToCover\":[\"Data availability\",\"Rapid policy changes\",\"Inconsistent payer policy transparency\",\"Scope creep\"],\"criticalDecisionsQuestionsConfirmations\":[\"What dependencies could delay the work?\",\"What scope trade-offs are acceptable?\"]},{\"slideTitle\":\"Immediate next steps\",\"purpose\":\"Lock down actions needed to start the research efficiently.\",\"keyTopicsToCover\":[\"Confirm payer list and comparator set\",\"Confirm source priorities\",\"Assign owners for inputs and review\"],\"criticalDecisionsQuestionsConfirmations\":[\"What is due from the client and by when?\",\"What is the date for the next working session?\"]}]},\"4. Materials and inputs to request\":{\"materials\":[\"List of target payers, PBMs, and Medicare Advantage organizations\",\"Any internal payer strategy or launch planning materials\",\"Priority competitor and product list\",\"Previous market access or payer research\",\"Preferred output format and level of detail\",\"Any known policy documents or stakeholder insights already collected\"],\"stakeholder_inputs\":[\"Business questions the research must answer\",\"Preferred evidence thresholds\",\"Internal views on likely access barriers\",\"Reviewers and approvers for interim/final outputs\"]},\"5. Risks and open questions\":{\"risks\":[\"Payer policies may change during the research window.\",\"Public documentation may not fully reflect real decision-making.\",\"Coverage approaches may vary significantly by payer segment and line of business.\",\"Evidence expectations may differ across commercial and MA plans.\"],\"open_questions\":[\"Which payers are priority versus illustrative?\",\"Should the analysis separate obesity-only policies from broader cardiometabolic management?\",\"How deep should competitor contracting analysis go?\",\"What is the minimum evidence package needed to support launch planning?\"]},\"6. Immediate next steps\":{\"actions\":[{\"action\":\"Confirm final research scope, payer universe, and competitor set\",\"owner\":\"Client + project lead\"},{\"action\":\"Share any existing market access materials and prior analyses\",\"owner\":\"Client\"},{\"action\":\"Finalize source strategy and analytic framework\",\"owner\":\"Project team\"},{\"action\":\"Set review cadence and milestone dates\",\"owner\":\"Client + project lead\"}]}}}",
"providerResponseId": "resp_0ef6a74146008e0d006a04dfc9cc008194ab3ff826ba42aca5"
}